AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10474283 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine 5 to 20 mg/day
Number of subjects: 828
Study 10474283 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol 5 to 20 mg/day
Number of subjects: 828
Study 8557891 — intervention group
Group type: EXPERIMENTAL
Intervention: Stent group
Number of subjects: 516
Study 8557891 — intervention group
Group type: COMPARATOR
Intervention: Balloon angioplasty group
Number of subjects: 516
Study 1987616 — intervention group
Group type: EXPERIMENTAL
Intervention: UDCA
Number of subjects: 141
Study 1987616 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 141
Study 1987616 — intervention group
Group type: COMPARATOR
Intervention: UDCA or Placebo
Number of subjects: 141
Study 6138082 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 10 mg (oral)
Number of subjects: 6
Study 6138082 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 20 mg (oral)
Number of subjects: 6
Study 6138082 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 40 mg (oral)
Number of subjects: 6
Study 6138082 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 0.15 mg kg‐1 (intravenous)
Number of subjects: 6
Study 6138082 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 3890448 — intervention group
Group type: EXPERIMENTAL
Intervention: Evening primrose oil (Efamol)
Number of subjects: 99
Study 3890448 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 99
Study 31874050 — intervention group
Group type: EXPERIMENTAL
Intervention: 50,000 IU vitamin D3 pearl once weekly for 12 weeks
Number of subjects: 44
Study 31874050 — intervention group
Group type: COMPARATOR
Intervention: Placebo once weekly for 12 weeks
Number of subjects: 44
Study 31874050 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Vitamin D and Placebo)
Number of subjects: 44
Study 29891272 — intervention group
Group type: EXPERIMENTAL
Intervention: Negatively framed questionnaires (PHQ-2, PCS-4, PROMIS depression CAT)
Number of subjects: 134
Study 29891272 — intervention group
Group type: COMPARATOR
Intervention: Positively framed questionnaires (PSEQ-2)
Number of subjects: 134
Study 27753609 — intervention group
Group type: EXPERIMENTAL
Intervention: FP plus Bev (arm A)
Number of subjects: 837
Study 27753609 — intervention group
Group type: EXPERIMENTAL
Intervention: Bev alone (arm B)
Number of subjects: 837
Study 27753609 — intervention group
Group type: COMPARATOR
Intervention: No active treatment (arm C)
Number of subjects: 837
Study 23939383 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast-enhanced magnetic resonance angiography (MRA)
Number of subjects: 79
Study 23939383 — intervention group
Group type: COMPARATOR
Intervention: Intra-arterial digital subtraction angiography (DSA)
Number of subjects: 79
Study 23299716 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifidobacterium lactis NCC2818
Number of subjects: 0
Study 23299716 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 20885298 — intervention group
Group type: EXPERIMENTAL
Intervention: tinzaparin (175 IU/kg/day)
Number of subjects: 102
Study 20885298 — intervention group
Group type: COMPARATOR
Intervention: acenocoumarol
Number of subjects: 102
Study 20885298 — intervention group
Group type: EXPERIMENTAL
Intervention: tinzaparin
Number of subjects: 102
Study 18283386 — intervention group
Group type: EXPERIMENTAL
Intervention: Teriparatide (20 microg/day) added to raloxifene
Number of subjects: 198
Study 18283386 — intervention group
Group type: EXPERIMENTAL
Intervention: Teriparatide (20 microg/day) added to alendronate
Number of subjects: 198
Study 18283386 — intervention group
Group type: EXPERIMENTAL
Intervention: Teriparatide (20 microg/day) switched from raloxifene
Number of subjects: 198
Study 18283386 — intervention group
Group type: EXPERIMENTAL
Intervention: Teriparatide (20 microg/day) switched from alendronate
Number of subjects: 198
Study 18283386 — intervention group
Group type: COMPARATOR
Intervention: Control (raloxifene or alendronate)
Number of subjects: 198
Study 16093267 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone therapy (5 mg Androderm)
Number of subjects: 76
Study 16093267 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone therapy
Number of subjects: 76
Study 16093267 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study 14605927 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified cutting seton
Number of subjects: 34
Study 14605927 — intervention group
Group type: COMPARATOR
Intervention: Conventional cutting seton
Number of subjects: 34
Study 10953135 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 implant
Number of subjects: 51
Study 10953135 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 implants
Number of subjects: 51
Study 8793613 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg promethazine
Number of subjects: 60
Study 8793613 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg ranitidine
Number of subjects: 60
Study 8793613 — intervention group
Group type: EXPERIMENTAL
Intervention: both drugs
Number of subjects: 60
Study 8793613 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 60
Study 1616516 — intervention group
Group type: EXPERIMENTAL
Intervention: Activated charcoal 50 gm every hour for 8 hours (cumulative dose 150 gm)
Number of subjects: 5
Study 1616516 — intervention group
Group type: EXPERIMENTAL
Intervention: Activated charcoal 25 gm every 2 hours for 8 hours (cumulative dose 150 gm)
Number of subjects: 5
Study 1616516 — intervention group
Group type: EXPERIMENTAL
Intervention: Activated charcoal 12.5 gm every hour for 8 hours (cumulative dose 150 gm)
Number of subjects: 5
Study 1616516 — intervention group
Group type: COMPARATOR
Intervention: Control phase (no activated charcoal, only aminophylline 8 mg/kg)
Number of subjects: 5
Study 6437264 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral sodium cromoglycate (200-1600 mg/24 h)
Number of subjects: 34
Study 6437264 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 30682069 — intervention group
Group type: EXPERIMENTAL
Intervention: SP‐AQ only
Number of subjects: 7000
Study 30682069 — intervention group
Group type: EXPERIMENTAL
Intervention: SP‐AQ plus LNS
Number of subjects: 7000
Study 30682069 — intervention group
Group type: COMPARATOR
Intervention: LNS
Number of subjects: 7000
Study 30682069 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional status
Number of subjects: 7000
Study 30107641 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-step nasal spray (SP)
Number of subjects: 138
Study 30107641 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular simulated naloxone (IM)
Number of subjects: 138
Study 30107641 — intervention group
Group type: COMPARATOR
Intervention: Multi-step atomized nasal spray (AT)
Number of subjects: 138
Study 25987647 — intervention group
Group type: EXPERIMENTAL
Intervention: ≥5% reduction in sedentary time (N = 27)
Number of subjects: 96
Study 25987647 — intervention group
Group type: EXPERIMENTAL
Intervention: 0-4.99% reduction in sedentary time (N = 29)
Number of subjects: 96
Study 25987647 — intervention group
Group type: COMPARATOR
Intervention: Increase in sedentary time (N = 40)
Number of subjects: 96
Study 24033356 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasudil (30 mg intravenous administration)
Number of subjects: 23
Study 24033356 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 23421087 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxalin (0.05%)
Number of subjects: 4674
Study 19427798 — intervention group
Group type: COMPARATOR
Intervention: Ankle brace (lace-up brace)
Number of subjects: 24
Study 19427798 — intervention group
Group type: COMPARATOR
Intervention: Cryotherapy (ice)
Number of subjects: 24
Study 19427798 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined ankle bracing and joint cooling
Number of subjects: 24
Study 17663619 — intervention group
Group type: EXPERIMENTAL
Intervention: Face-to-face or Internet intervention
Number of subjects: 314
Study 17663619 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily weighing
Number of subjects: 314
Study 16105050 — intervention group
Group type: EXPERIMENTAL
Intervention: irbesartan 300 mg once daily
Number of subjects: 52
Study 16105050 — intervention group
Group type: EXPERIMENTAL
Intervention: irbesartan 600 mg once daily
Number of subjects: 52
Study 16105050 — intervention group
Group type: EXPERIMENTAL
Intervention: irbesartan 900 mg once daily
Number of subjects: 52
Study 12392585 — intervention group
Group type: EXPERIMENTAL
Intervention: Nevirapine
Number of subjects: 173
Study 10658441 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term treatment protocol (STP) with PGE1 alpha-ciclodestrina: 2-hour infusions (20 micrograms in the morning, 40 micrograms in the afternoon on the first day; 60 micrograms b.i.d. on the second day) for 2 days, repeated at weeks 4, 8, 12.
Number of subjects: 120
Study 10658441 — intervention group
Group type: COMPARATOR
Intervention: Long-term treatment protocol (LTP) with PGE1 alpha-ciclodestrina: 2-hour infusions (60 micrograms PGE1 alpha-ciclodestrina, 5 days each week for 4 weeks, then twice a week for 4 weeks).
Number of subjects: 120
Study 10658441 — intervention group
Group type: EXPERIMENTAL
Intervention: Both STP and LTP
Number of subjects: 120
Study 10658441 — intervention group
Group type: EXPERIMENTAL
Intervention: STP
Number of subjects: 120
Study 10658441 — intervention group
Group type: COMPARATOR
Intervention: LTP
Number of subjects: 120
Study 7709902 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride-releasing elastomers
Number of subjects: 4
Study 7709902 — intervention group
Group type: COMPARATOR
Intervention: Conventional elastomers
Number of subjects: 4
Study 2491219 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcitonin 0.0175 iu/kg per min
Number of subjects: 7
Study 2491219 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcitonin 0.0350 iu/kg per min
Number of subjects: 7
Study 2491219 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcitonin
Number of subjects: 7
Study 2491219 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 331627 — intervention group
Group type: COMPARATOR
Intervention: Amikacin sulfate (15 mg./Kg.)
Number of subjects: 50
Study 331627 — intervention group
Group type: COMPARATOR
Intervention: Amikacin sulfate (7.5 mg./Kg.)
Number of subjects: 50
Study 30871549 — intervention group
Group type: EXPERIMENTAL
Intervention: Insoles with LLD correction (70% correction of LLD) used for 8 hours per day
Number of subjects: 387
Study 30871549 — intervention group
Group type: COMPARATOR
Intervention: Insoles without LLD correction
Number of subjects: 387
Study 27884722 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential anthracycline-taxane chemotherapy
Number of subjects: 1363
Study 27884722 — intervention group
Group type: COMPARATOR
Intervention: Epirubicin/fluorouracil/cyclophosphamid chemotherapy (FEC)
Number of subjects: 1363
Study 26498289 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS (2 mA for 20 min, 5 sessions over 5 consecutive days)
Number of subjects: 22
Study 26498289 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation (5 sessions over 5 consecutive days)
Number of subjects: 22
Study 24709403 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-dimensional ultrasonography (3DU)
Number of subjects: 75
Study 23063373 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous immunotherapy (SCIT) with Standardized Quality (SQ) 6-grass mix and rye allergen extract, 8-day up-dosing schedule to 10,000 SQ-units (6 daily injections) followed by 2 maintenance injections of 10,000 SQ-units at intervals of 2 and 4 weeks.
Number of subjects: 148
Study 23063373 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 148
Study 20218422 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated serum TRACP-5b levels
Number of subjects: 820
Study 20218422 — intervention group
Group type: COMPARATOR
Intervention: Control group (asymptomatic subjects)
Number of subjects: 820
Study 17534231 — intervention group
Group type: EXPERIMENTAL
Intervention: Biphasic electrical stimulation up to 20 ma for 30 minutes, 3 times a week for 4 weeks in a 32 degrees C room.
Number of subjects: 20
Study 17534231 — intervention group
Group type: EXPERIMENTAL
Intervention: Biphasic electrical stimulation in a warm room.
Number of subjects: 20
Study 15157949 — intervention group
Group type: EXPERIMENTAL
Intervention: Narcoleptics
Number of subjects: 39
Study 15157949 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 39
Study 11522698 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled insulin regimen
Number of subjects: 69
Study 11522698 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous insulin regimen
Number of subjects: 69
Study 11522698 — intervention group
Group type: EXPERIMENTAL
Intervention: HbA(1c) change
Number of subjects: 69
Study 9478090 — intervention group
Group type: EXPERIMENTAL
Intervention: Workers producing organophosphorous pesticides
Number of subjects: 120
Study 9478090 — intervention group
Group type: EXPERIMENTAL
Intervention: Workers producing chlorfenvinphos
Number of subjects: 120
Study 7944467 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraarterial chemotherapy with MTX, ADR, and CDDP
Number of subjects: 88
Study 7944467 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose of CDDP (more than 100 mg/m2)
Number of subjects: 88
Study 7944467 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraarterial chemotherapy (general)
Number of subjects: 88
Study 2886223 — intervention group
Group type: EXPERIMENTAL
Intervention: Amantadine
Number of subjects: 22
Study 2886223 — intervention group
Group type: COMPARATOR
Intervention: Benztropine
Number of subjects: 22
Study 28833613 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediately provisionalised with a non-occluding temporary crown
Number of subjects: 24
Study 28833613 — intervention group
Group type: COMPARATOR
Intervention: Control group (left without a crown)
Number of subjects: 24
Study 27655326 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT) applied before plyometric exercise
Number of subjects: 24
Study 27655326 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT) applied after plyometric exercise
Number of subjects: 24
Study 27655326 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 24
Study 24597534 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary care intervention to reduce sitting time over six months (Intervention Group - IG)
Number of subjects: 232
Study 24597534 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary care intervention to reduce sitting time (Intervention Group - IG)
Number of subjects: 232
Study 23113898 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent exercise (n = 25), 90 min/d, 2 d/wk for 12 months
Number of subjects: 50
Study 23113898 — intervention group
Group type: COMPARATOR
Intervention: Education control group (n = 25)
Number of subjects: 50
Study 20561460 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive educational workshop and chart audit with feedback on cholesterol management
Number of subjects: 340
Study 20561460 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 340
Study 16973692 — intervention group
Group type: EXPERIMENTAL
Intervention: Face Cooling (FC)
Number of subjects: 10
Study 16351360 — intervention group
Group type: EXPERIMENTAL
Intervention: African American prime
Number of subjects: 0
Study 16351360 — intervention group
Group type: EXPERIMENTAL
Intervention: Number 7 prime
Number of subjects: 0
Study 16351360 — intervention group
Group type: EXPERIMENTAL
Intervention: Low self-monitors
Number of subjects: 0
Study 12081819 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 g isolated soy protein (ISP)
Number of subjects: 130
Study 12081819 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 g isolated soy protein (ISP)
Number of subjects: 130
Study 12081819 — intervention group
Group type: COMPARATOR
Intervention: Casein
Number of subjects: 130
Study 7560560 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple-gate screening procedure
Number of subjects: 7231
Study 7560560 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive screens
Number of subjects: 7231
Study 7560560 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative screens
Number of subjects: 7231
Study 7560560 — intervention group
Group type: COMPARATOR
Intervention: Low-risk comparison children
Number of subjects: 7231
Study 7560560 — intervention group
Group type: EXPERIMENTAL
Intervention: Gating measures
Number of subjects: 7231
Study 7560560 — intervention group
Group type: EXPERIMENTAL
Intervention: Family process variables (poor family communication, poor maternal coping skills, external parent locus of control)
Number of subjects: 7231
Study 2096603 — intervention group
Group type: EXPERIMENTAL
Intervention: Lyophilized bovine pericardium
Number of subjects: 102
Study 2096603 — intervention group
Group type: COMPARATOR
Intervention: Lyophilized human dura mater
Number of subjects: 102
Study 556111 — intervention group
Group type: EXPERIMENTAL
Intervention: Anxiety Management Training (AMT)
Number of subjects: 14
Study 556111 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 14
Study 31301191 — intervention group
Group type: EXPERIMENTAL
Intervention: Music & Memory program (individualized music delivered at early signs of agitation)
Number of subjects: 45
Study 28864134 — intervention group
Group type: EXPERIMENTAL
Intervention: Left cardiac sympathetic denervation (LCSD) as an adjunct to guideline recommended medical therapy
Number of subjects: 4
Study 28864134 — intervention group
Group type: COMPARATOR
Intervention: Guideline recommended medical therapy
Number of subjects: 4
Study 26945176 — intervention group
Group type: EXPERIMENTAL
Intervention: 1‐DAY ACUVUE DEFINE (AD)
Number of subjects: 24
Study 26945176 — intervention group
Group type: EXPERIMENTAL
Intervention: 1‐DAY ACUVUE DEFINE with Lacreon (ADL)
Number of subjects: 24
Study 26945176 — intervention group
Group type: COMPARATOR
Intervention: 1‐DAY ACUVUE MOIST (AM)
Number of subjects: 24
Study 26945176 — intervention group
Group type: COMPARATOR
Intervention: No Lens Wear (NLW)
Number of subjects: 24
Study 23725997 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent stereotactic radiosurgery (SRS) and bevacizumab (BVZ)
Number of subjects: 15
Study 21214392 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT) using a 50 mW 660 nm GaAlAs laser, irradiated at 1.75 W/cm² for 28 seconds per point, at three points around the cryosurgical site, immediately after treatment and at 48 and 72 hours post-treatment.
Number of subjects: 18
Study 21214392 — intervention group
Group type: COMPARATOR
Intervention: Cryosurgical treatment without LLLT (Non-LLLT group).
Number of subjects: 18
Study 19447369 — intervention group
Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (PDT) using a bioadhesive patch loaded with 38 mg cm(‐2) aminolevulinic acid, administered in one or two cycles.
Number of subjects: 23
Study 19447369 — intervention group
Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (PDT) using a bioadhesive patch loaded with 38 mg cm(‐2) aminolevulinic acid.
Number of subjects: 23
Study 17277911 — intervention group
Group type: EXPERIMENTAL
Intervention: Reboxetine
Number of subjects: 10
Study 17277911 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 15717704 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisatracurium 0.15 mg kg(‐1)
Number of subjects: 40
Study 15717704 — intervention group
Group type: EXPERIMENTAL
Intervention: Vecuronium 0.1 mg kg(‐1)
Number of subjects: 40
Study 11258644 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C supplementation (1 g dose, 2 hours before exercise)
Number of subjects: 9
Study 11258644 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 9696472 — intervention group
Group type: EXPERIMENTAL
Intervention: MMPI-2 assessment
Number of subjects: 240
Study 9696472 — intervention group
Group type: EXPERIMENTAL
Intervention: External measures relevant to pain
Number of subjects: 240
Study 9696472 — intervention group
Group type: EXPERIMENTAL
Intervention: MMPI-2 dimensions
Number of subjects: 240
Study 9696472 — intervention group
Group type: EXPERIMENTAL
Intervention: MMPI-2 research
Number of subjects: 240
Study 8026290 — intervention group
Group type: EXPERIMENTAL
Intervention: Polymeric dressing
Number of subjects: 19
Study 8026290 — intervention group
Group type: COMPARATOR
Intervention: Conventional wet‐to‐dry saline dressings
Number of subjects: 19
Study 8026290 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy (crossed over to polymeric dressing)
Number of subjects: 19
Study 2531184 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilazapril (2.5 mg daily)
Number of subjects: 18
Study 2531184 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (120 mg daily)
Number of subjects: 18
Study 2531184 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of cilazapril and propranolol
Number of subjects: 18
Study 2531184 — intervention group
Group type: COMPARATOR
Intervention: Propranolol alone
Number of subjects: 18
Study 2531184 — intervention group
Group type: COMPARATOR
Intervention: Cilazapril alone
Number of subjects: 18
Study 2531184 — intervention group
Group type: COMPARATOR
Intervention: Combination of both drugs
Number of subjects: 18
Study 4564559 — intervention group
Group type: EXPERIMENTAL
Intervention: ADV‐21 vaccine (10^6.4 TCID(50))
Number of subjects: 27
Study 4564559 — intervention group
Group type: EXPERIMENTAL
Intervention: ADV‐21 vaccine (10^6.8 TCID(50))
Number of subjects: 27
Study 4564559 — intervention group
Group type: EXPERIMENTAL
Intervention: ADV‐21 vaccine (10^4.6 TCID(50))
Number of subjects: 27
Study 4564559 — intervention group
Group type: EXPERIMENTAL
Intervention: ADV‐21 vaccine (10^2.4 TCID(50))
Number of subjects: 27
Study 4564559 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 27
Study 31556131 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated BP at 28 weeks’ gestation
Number of subjects: 329
Study 31556131 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated BP at 34 weeks’ gestation
Number of subjects: 329
Study 31556131 — intervention group
Group type: COMPARATOR
Intervention: Normal BP in pregnancy
Number of subjects: 329
Study 28538676 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet (MedDiet)
Number of subjects: 166
Study 28538676 — intervention group
Group type: COMPARATOR
Intervention: Habitual diet (HabDiet)
Number of subjects: 166
Study 24115184 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium 2000 mg/d
Number of subjects: 0